בינוקריט 20000 יחבל  0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 20000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 3000 יחבל  0.3 מל ישראל - עברית - Ministry of Health

בינוקריט 3000 יחבל 0.3 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 40000 יחבל  1 מל ישראל - עברית - Ministry of Health

בינוקריט 40000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

פלומיסט קואדריוואלנט ישראל - עברית - Ministry of Health

פלומיסט קואדריוואלנט

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

ערבה 10 מג ישראל - עברית - Ministry of Health

ערבה 10 מג

sanofi israel ltd - leflunomide - טבליות מצופות פילם - leflunomide 10 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

ערבה 20 מג ישראל - עברית - Ministry of Health

ערבה 20 מג

sanofi israel ltd - leflunomide - טבליות מצופות פילם - leflunomide 20 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

סטיבקס ישראל - עברית - Ministry of Health

סטיבקס

neopharm scientific ltd - cannabidiol drug substance ( cbd bds ); delta-9-tetrahydrocannabinol drug substance ( thc bds ) - ספריי לחלל הפה - cannabidiol drug substance ( cbd bds ) 25 mg / 1 ml; delta-9-tetrahydrocannabinol drug substance ( thc bds ) 27 mg / 1 ml - nabiximols - sativex is indicated, as add-on treatment, for symptom relief in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other medication and who demonstrate at least 20 % improvement in spasticity related symptoms during a four week trial of therapy.sativex is indicated as adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis in adults.

Devices for reconstitution, transfer and administration of drugs in a closed system ישראל - עברית - Ministry of Health

devices for reconstitution, transfer and administration of drugs in a closed system

גאמידה בע"מ - רופא - העברת נוזלים ישירה במערכת סגורה, למניעת חדירת אוויר למערכת ובריחת נוזלים מהמערכת

Tevadaptor - Closed drug reconstitution system ישראל - עברית - Ministry of Health

tevadaptor - closed drug reconstitution system

teva medical ltd. - migada - אחות - see attached document : us fda 510(k) k051669 approved indications for use